Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584847 | 1.00 | ALDH1A1 (0.47) | ALDH1A1GLAACHEKMT2AMEN1 | |
| SCHEMBL7484195 | 0.77 | ACHE (0.68) | ACHEKMT2AMEN1L3MBTL1ADRA1D | |
| SCHEMBL5584701 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KMT2AL3MBTL1TDP1 | |
| SCHEMBL5584698 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KMT2AL3MBTL1TDP1 | |
| SCHEMBL29618932 | 0.73 | ALDH1A1 (0.67) | ALDH1A1GLAKMT2AMEN1L3MBTL1 | |
| SCHEMBL3412321 | 0.73 | ALDH1A1 (0.62) | ALDH1A1GLAKMT2AMEN1ADRA1A | |
| SCHEMBL4276592 | 0.73 | ALDH1A1 (0.67) | ALDH1A1GLAKMT2AMEN1L3MBTL1 | |
| SCHEMBL1745602 | 0.73 | ALDH1A1 (0.66) | ALDH1A1GLAKMT2AMEN1ADRA1A | |
| SCHEMBL4513254 | 0.72 | KMT2A (0.64) | ACHEKMT2AMEN1MAPK1L3MBTL1 | |
| SCHEMBL14537170 | 0.72 | MAPK1 (0.56) | ALDH1A1ACHEKMT2AMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | ALDH1A1 443/4885GLA 3730/4885ACHE 714/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | ALDH1A1 443/4885GLA 3730/4885ACHE 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.